Table 1 Baseline characteristics of the enrolled men with T2DM
From: Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
Study part (n): group (n) | Part A (n = 27): Placebo onlya (n = 9) | Part A (n = 27): VEGF-A mRNA/placeboa (n = 18) | Part B (n = 15): VEGF-A mRNA/placebob (n = 15) |
|---|---|---|---|
Age, years | |||
Median (range) | 58.0 (47, 65) | 58.5 (41, 65) | 56.0 (44, 64) |
Race, white | |||
n (%) | 9 (100.0) | 18 (100.0) | 15 (100.0) |
BMI, kg/m2 | |||
Median (range) | 30.80 (27.5–34.5) | 29.40 (25.2–33.3) | 30.10 (22.2–35.0) |
Medical history, n (%) | |||
[>30% in any group] | |||
Hypertension | 5 (55.6) | 6 (33.3) | 11 (73.3) |
Hyperlipidemia | 4 (44.4) | 5 (27.8) | 6 (40.0) |
Appendectomy | 1 (11.1) | 2 (11.1) | 8 (53.3) |
Inguinal hernia repair | 4 (44.4) | 3 (16.7) | 1 (6.7) |
Seasonal allergy | 3 (33.3) | 3 (16.7) | 3 (20.0) |
